Skip to content

Study · Not a test of the peptide alone · 2024

1 result

Platelet membrane-coated bio-nanoparticles of indocyanine green/elamipretide for NIR diagnosis and antioxidant therapy in acute kidney injury.

Yao S, Wu D, Hu X, Chen Y, Fan W, Mou X, Cai Y, Yang X

Acta biomaterialia18 Nov 2023Cited by 32 (Europe PMC)

PMID37981044 (opens in a new tab)DOI10.1016/j.actbio.2023.11.010 (opens in a new tab)PepBankPUB-37981044
Publisher pagePubMedAsk about this study
Jump to 1 result

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study1

No result from this study comes from a test of the peptide.

Studies that did not test the peptide alone1

In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. These results are not evidence about taking Elamipretide (SS-31).

  1. 01AnimalNot a test of Elamipretide (SS-31) aloneOther designPharmacokinetics

    The Platelet membranes-ICG-SS31-PLGA nano-system accumulated within the kidney as acute kidney injury progressed.

    In plain wordsA nanoparticle carrying SS31 and a dye built up in the kidney as kidney injury worsened.

    Peptide
    Elamipretide (SS-31)
    Outcome
    IncreaseKidney accumulation of PISP nano-system
    Study

    n: not reported in source

    Kidney injury (not stated)
    Outcome group
    Pharmacokinetics · Kidney and urinary

    Source sentences

    Summary
    This approach allowed for the accumulation of PISP within the kidney as the disease progresses.
    1 context sentence
    Summary · context
    In this study, we aimed to address these challenges by developing a nano-system called Platelet membranes-ICG-SS31-PLGA (PISP), which was designed to selectively target to the kidney site, taking advantage of the natural tendency of platelets to accumulate at sites of vascular injury.

    In this study, Elamipretide (SS-31) was a lab tool or a carrier, part of a mix, or the subject of a lab method. This result is not evidence about taking Elamipretide (SS-31).

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    10 Oct 2026, 08:19 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 02:47 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.